Invivyd (NASDAQ:IVVD) Insider Julie Green Sells 18,425 Shares of Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Julie Green sold 18,425 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total transaction of $15,477.00. Following the completion of the sale, the insider directly owned 168,937 shares in the company, valued at approximately $141,907.08. The trade was a 9.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Julie Green also recently made the following trade(s):

• On Monday, August 17th, Julie Green sold 22,355 shares of Invivyd stock. The shares were sold at an average price of $0.72, for a total value of $16,095.60.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $0.87 on Wednesday. The stock has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The firm’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $1.23. Invivyd, Inc. has a 12 month low of $0.48 and a 12 month high of $3.07.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative net margin of 183.90% and a negative return on equity of 59.73%. The firm had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Analysts anticipate that Invivyd, Inc. will post -0.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Invivyd

A number of hedge funds and other institutional investors have recently modified their holdings of IVVD. United Capital Financial Advisors LLC acquired a new stake in Invivyd in the second quarter valued at $84,000. Bank of America Corp DE purchased a new stake in Invivyd in the second quarter valued at approximately $311,000. Jupiter Topco LLC acquired a new stake in Invivyd during the 2nd quarter worth $30,048,000. ADAR1 Capital Management LLC acquired a new stake in shares of Invivyd during the second quarter worth about $3,322,000. Finally, The Manufacturers Life Insurance Company purchased a new position in shares of Invivyd in the 2nd quarter valued at approximately $52,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
• Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
• Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.

Wall Street Analyst Weigh In

Several research firms have commented on IVVD. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research note on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Finally, Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Invivyd currently has a consensus rating of “Hold” and a consensus target price of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.